临床试验/NCT07096999

NCT07096999招募中不适用

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

University of Michigan Rogel Cancer Center1 个研究点分布在 1 个国家目标入组 60 人开始时间: 2025年1月23日最近更新: 2026年7月27日

适应症

干预措施

试验速览

阶段: 不适用
状态: 招募中
发起方: University of Michigan Rogel Cancer Center
入组人数: 60
试验地点: 1
主要终点: Response and toxicity following 177Lu-RLT

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: Male
接受健康志愿者: 否

入选标准

•* 177Lu-617 PSMA treatment scheduled for mCRPC
•Clinically stable as determined by the nuclear medicine clinicians
•≥ 18 years of age
•Willing and able to provide informed consent

排除标准

•Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed

研究组 & 干预措施

Observational

Patients receive standard care Pluvicto and undergo Lu-177 SPECT/CT scans on study. Patients may also undergo optional 99mTc-SC SPECT/CT scan for bone marrow dosimetry prior to cycle 1. In addition, patients have their medical records reviewed on study.

干预措施: Non-Interventional Study (Other)

结局指标

主要结局

Response and toxicity following 177Lu-RLT

时间窗: Up to 4 years

Association between absorbed dose and effect (response/toxicity) following 177Lu-RLT

次要结局

Build and test models(Up to 4 years)

研究者

发起方

University of Michigan Rogel Cancer Center

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

招募中

不适用

177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer

NCT05613738Peking Union Medical College Hospital9

已完成

不适用

RAD327 Lu-177 Dosimetry with SPECT/CTneuroendocrine tumorsC80C17C25.9Malignant neoplasm, without specification of siteMalignant neoplasm of small intestinePancreas, unspecified

DRKS00011489niversitätsklinikum Magdeburg6

招募中

不适用

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)Metastatic Castration-resistant Prostate Cancer

NCT05823402BAMF Health30

撤回

2 期

PSMA-PET/MRI Low- and Intermediate-Risk Prostate CancerProstate Cancer

NCT04243941UNC Lineberger Comprehensive Cancer Center

Unknown

2 期

177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer

NCT04188587Nanjing First Hospital, Nanjing Medical University30